Study of TQB2450 plus progestin for uterine cancer patients wanting to keep fertility
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an immunotherapy drug (TQB2450) with a hormone treatment (progestin) for patients with a specific type of early-stage uterine cancer who wish to preserve their ability to have children. The goal is to see if this approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 45 years old.
- You have been diagnosed with endometrioid endometrial cancer that is low grade (grade 1 or 2) and has not invaded deep into the uterine muscle.
- Your cancer shows a specific genetic feature called MMR deficiency (MMRd).
- You want to preserve your fertility or keep your uterus.
- You have not had prior treatment with high-dose progesterone or certain oral contraceptives for more than 1 month in the last 3 months.
- You do not smoke more than 15 cigarettes per day.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a tailored approach to preserve fertility in women with early-stage endometrial cancer, using medications like hormones and immunotherapy based on the tumor's molecular subtype. It aims to avoid hysterectomy and keep the uterus intact.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests whether adding a targeted drug (fruquintinib) to standard chemotherapy works better than chemotherapy alone as the first treatment for advanced or recurrent endometrial cancer that is pMMR. It may help control the cancer for a longer time.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.